Next-Gen Oral SERD Cuts Recurrence Risk in Early Breast Cancer

(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen-receptor degrader (SERD) giredestrant significantly reduced recurrence risk compared with standard…